Cite
HARVARD Citation
Zeidan, A. et al. (2015). Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal of comparative effectiveness research. pp. 327-340. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zeidan, A. et al. (2015). Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal of comparative effectiveness research. pp. 327-340. [Online].